2008 HEDIS® measures
Updated 6/1/2008
The tables below explain the HEDIS measures for two types of care: preventive health care (children and adolescents, women and adolescent girls, adults, and seniors) and condition-specific care. Red text indicates a change or update to criteria for 2008.
New this year
| Children and adolescents |
|
Measure |
Care, screening, or test needed |
|
Lead screening in children (Medicaid only) Children age 2 |
Children who received at least one capillary or venous lead screening test on or before their second birthday. |
| Adults |
|
Pharmacotherapy management of COPD exacerbation Adults age 40 or older
|
Adults aged 40 or older by December 31 of the measurement year who had an acute inpatient discharge or an ED encounter with a principal diagnosis of COPD who were dispensed both:
- A systemic corticosteroid within 14 days of discharge
- Bronchodilator within 30 days of discharge
NOTE: the eligible population for this measure is based on the discharges and ED visits not the patient. It is possible for the denominator for this measure to include multiple events for the same patient. |
Preventive health care
| Children and adolescents |
|
Measure |
Care, screening, or test needed |
|
Well-child exams
Ages 0-15 months |
6 well-care visits (at least 2 weeks apart) with a PCP. Must show evidence of all of the following:
- Health and development history (physical and mental)
- Physical exam
- Health education/anticipatory guidance
|
|
Well-child exams
Ages 3-6 years |
Annual well-care visit with a PCP each year. Must show evidence of all of the following:
- Health and development history (physical and mental)
- Physical exam
- Health education/anticipatory guidance
|
|
Well-child exams
Ages 12-21 years |
Annual well-care visit with a PCP or OB/GYN. Must show evidence of all of the following:
- Health and development history (physical and mental)
- Physical exam
- Health education/anticipatory guidance
|
Lead screening in children (Medicaid only)
Children aged 2 (new for 2008)
|
Children who received at least one capillary or venous lead screening test on or before their second birthday. |
|
Childhood immunization
Series must be completed by the 2nd birthday |
- 4 DTaP/DT (none prior to 42 days of age)
- 3 IPV (none prior to 42 days of age)
- 1 MMR
- 3 HIB (none prior to 42 days of age)
- 3 hepatitis B
- 1 VZV, or documented chicken pox disease (or positive serology) occurring prior to 2nd birthday
- 4 pneumococcal conjugate
|
|
Adolescent immunization
Series must be completed by the 13th birthday RETIRED |
- 2 MMR (on or between 1st and 4th birthday) or 1 MMR (on or between 4th and 13 birthday)
- 3 hepatitis B
- 1 VZV or documented chickenpox disease (or positive serology) occurring prior to 13th birthday
This measure has been retired by NCQA. A refocused measure is being tested for a future HEDIS® year. |
Treatment of children with upper respiratory infections
Ages 3 months- 18 years |
Prescription for antibiotic not dispensed on or within three days of the URI diagnosis
Exclusions:
- Encounters with > 1 diagnosis
- Children with a history of antibiotic Rx within 30 days of encounter
|
|
Appropriate testing of children with pharyngitis
Ages 2-18 years |
Children diagnosed with pharyngitis who were prescribed an antibiotic and also received a Group A streptococcus test 3 days before or 3 days after the prescription
Exclusions:
- Encounters with > 1 diagnosis
- Children with a history of antibiotic Rx within 30 days of encounter
|
Follow-up care for children prescribed ADD/ADHD medication
Ages 6-12 years |
Children who received an initial prescription for ADD/ADHD medication and:
- Received at least one follow-up visit with a prescriber within 30 days of initiation of medication
- Remained on the medication for at least 210 days and who, in addition to the visit in the initiation phase, had at least two visits between four weeks and 9 months
|
| Women and adolescent girls |
|
Measure |
Care, screening, or test needed |
|
Chlamydia screening
Age 16-25 and sexually active |
Women identified as presumed sexually active by pharmacy Rx data, or claims data indicating potential sexual activity
- Screening test for chlamydia yearly (consider urine screen)
Exclusions:
- Women who had a pregnancy test and received an Rx for Accutane (isotretinoin) or had an X-ray within 7 days
|
|
Cervical cancer screening
Age 21-64
|
PAP test within the measurement year or prior 2 years.
Exclusions:
- Women who have had a complete hysterectomy with no residual cervix.
|
|
Breast cancer screening
Age 40-69
|
Mammogram in the measurement year or one year prior.
Exclusions:
- Women who have had bilateral mastectomy (may occur on the same or separate dates)
|
|
Prenatal/ postpartum care
Pregnant women |
Prenatal visit within first trimester (or within 42 days of enrollment)
Postpartum visit between 21 and 56 days after delivery |
| Adults |
|
Measure |
Care, screening, or test needed |
|
Adult access to preventive/ ambulatory care
Ages 20 and over |
Annual ambulatory or preventive care visit |
|
Inappropriate antibiotic treatment for adults with acute bronchitis
Ages 18-64 |
Adults diagnosed with acute bronchitis who received an antibiotic Rx on or within 3 days of diagnosis
A lower rate represents better performance. |
|
Colorectal cancer screening
Ages 50-80 |
One or more of the following screenings:
- Fecal occult blood test (FOBT) yearly
- Flexible sigmoidoscopy every five years
- Double contrast barium enema (DCBE) every five years
- Colonoscopy every 10 years
Exclusions:
- Colorectal cancer
- Total colectomy
|
|
Annual monitoring for patients on persistent medications
Ages 18 and older |
Patients 18 and older on persistent medications (at least 180 days) who received annual monitoring.
|
Medications examined |
Annual monitoring |
|
ACE inhibitors/ARBs Digoxin Diuretics |
Serum potassium (K+), and either serum creatinine (SCr), or blood urea nitrogen (BUN) |
|
Anticonvulsants: Carbamazepine Phenobarbital Phenytoin Valproic acid |
Anticonvulsant drug serum concentration level |
Exclusion:
- Anyone with a hospitalization in the measurement year
|
| Seniors |
|
Measure |
Care, screening, or test needed |
|
Glaucoma screening in older adults Ages 65 and older |
Medicare members without a prior diagnosis of glaucoma or glaucoma suspect who received a glaucoma eye exam by an ophthalmologist or optometrist. |
Condition-specific care
| Alcohol and other drug dependence |
|
Measure |
Care, screening, or test needed |
|
Initiation and engagement of alcohol and other drug dependence treatment
Ages 13 and older |
Patients diagnosed with alcohol and other drug dependence who:
- initiate treatment within 14 days
- receive two additional AOD services within 30 days of initiation
|
| Asthma |
|
Measure |
Care, screening, or test needed |
|
Use of appropriate medications for people with asthma
Ages 5-56 years |
Children and adults identified with asthma who received Rx for long term control of asthma (inhaled corticosteroids, cromolyn sodium, nedocromil, leokotriene modifiers, and methylxanthines).
Exclusions:
- Patients with diagnosis of emphysema or COPD
Note: Long-acting beta-2 agonists do not count by themselves. They are considered add-on therapy. |
| Cardiac |
|
Measure |
Care, screening, or test needed |
Presistence of beta-blocker treatment after heart attack
Age 18 and older (new age range)
|
Patients who were hospitalized and discharged alive after an acute MI who:
- Received persistent treatment with beta-blockers for six months after discharge
Exclusions:
- Patients identified as having a contraindication to beta-blocker therapy
- Patients with a history of adverse reaction to beta-blocker therapy
|
|
Cholesterol management for patients with cardiovascular condition
Ages 18-75 |
Patients who were discharged alive for any of the following:
- Acute myocardial infarction
- Coronary artery bypass graft
- Percutaneous transluminal coronary angioplasty
Or who had:
- Diagnosis of ischemic vascular disease
Patient should have each of the following during the measurement year:
- LDL-C screening performed, LDL level < 100
|
|
Controlling high blood pressure
Age 18-85
|
Looks for control (< 140/90) in the most recent blood pressure reading in the medical record.
- Postural hierarchy is eliminated
- If there are multiple recorded BP on the same date, the lowest systolic and lowest diastolic reading will be used. If documented in the chart, home BP readings will be counted.
Exclusions:
- Patients with end stage renal disease (ESRD)
- Readings done the same day as major diagnostic, or surgical procedure, or during an emergency room visit
- Pregnant during the measurement year
|
| Chronic obstructive pulmonary disease (COPD) |
|
Measure |
Care, screening, or test needed |
|
Use of spirometry testing in the assessment and diagnosis of COPD
Ages 40 and older |
Adults with a new (within the measurement year) diagnosis or newly active COPD who received spirometry testing to confirm the diagnosis.
- Spirometry testing must occur 730 days prior to or 180 days after the diagnosing event.
|
|
Pharmacotherapy Management of COPD exacerbation
Adults 40 and older (new for 2008) |
Adults aged 40 or older by December 31 of the measurement year who had an acute inpatient discharge or an ED encounter with a principal diagnosis of COPD who were dispensed both:
- A systemic corticosteroid within 14 days of discharge
- Bronchodilator within 30 days of discharge
NOTE: the eligible population for this measure is based on the discharges and ED visits, not the patient. It is possible for the denominator for this measure to include multiple events for the same patient. |
| Depression |
|
Measure |
Care, screening, or test needed |
|
Antidepressant medication management
Ages 18 years and older |
Adults newly diagnosed with depression and treated with an antidepressant who received the following:
- Optimal practitioner contacts: 3 follow-up contacts with a diagnosis of depression within 12 weeks of the original diagnosing event to monitor progress. One contact must be with prescribing practitioner.
- Effective acute phase: filled sufficient number of Rx to allow for 84 days of continuous therapy.
- Effective continuation phase: filled sufficient number of Rx to allow for 180 days of continuous therapy.
To qualify as a new diagnosis, 2 criteria must be met:
- A 120-day (4 month) negative diagnosis history on or before the start date
- A 90-day (3 month) negative medication history on or before the start date
|
| Diabetes |
|
Measure |
Care, screening, or test needed |
|
Comprehensive diabetes care
Age 18-75
|
Yearly screening of the following:
- HbA1c testing
- HbA1c result > 9.0 = poor control
- HbA1c result < 7.0 = good control
- LDL-C
- LDL-C result < 100
- Retinal eye exam
- Nephropathy screening test or evidence of nephropathy
- Blood pressure collected as 2 measures
< 140/90 < 130/80 |
| Mental illness |
|
Measure |
Care, screening, or test needed |
|
Follow-up after hospitalization for mental illness
Age 6 and over |
Patients discharged from an inpatient mental health admission and receive:
- One follow-up encounter with a mental health provider on the date of discharge or up to 30 days after discharge.
|
| Osteoporosis |
|
Measure |
Care, screening, or test needed |
|
Osteoporosis management in women who had a fracture
Age 67 and older |
Women who received the following within 6 months of suffering a fracture:
- Bone mineral density (BMD) test
- Prescription for a drug to treat or prevent osteoporosis in six months after the fracture
Exclusions:
- Women who received screening and/or treatment in the year prior to the fracture. Fractures of the finger, toe, face and skull are not included in this measure.
|
| Tobacco users |
|
Measure |
Care, screening, or test needed |
|
Medical assistance with smoking cessation
Tobacco users age 18 and older |
Current smokers who were seen by a practitioner during the measurement year and:
- Received advice to quit
- Cessation medications were recommended and discussed
- Cessation methods were recommended or discussed
Information is received via CAHPS®** survey methodology. |
* HEDIS® is a registered trademark of NCQA.
** CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality.